Translate

Τρίτη 2 Ιουλίου 2019

Correction: Glucocorticoid impairs cell-cell communication by autophagy-mediated degradation of connexin 43 in osteocytes.
Correction: Glucocorticoid impairs cell-cell communication by autophagy-mediated degradation of connexin 43 in osteocytes. Oncotarget. 2019 Jun 18;10(40):4079 Authors: Gao J, Cheng TS, Qin A, Pavlos NJ, Wang T, Song K, Wang Y, Chen L, Zhou L, Jiang Q, Takayanagi H, Yan S, Zheng M Abstract [This corrects the article DOI: 10.18632/oncotarget.9034.].PMID: 31258851 [PubMed - in process]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma.
Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma. Oncotarget. 2019 Jun 18;10(40):4053-4068 Authors: Ichiyanagi O, Ito H, Naito S, Kabasawa T, Kanno H, Narisawa T, Ushijima M, Kurota Y, Ozawa M, Sakurai T, Nishida H, Kato T, Yamakawa M, Tsuchiya N Abstract Background: We investigated the roles of eIF4E phosphorylation (Ser209) in tumour recurrence after curative...
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications. Oncotarget. 2019 Jun 18;10(40):4038-4052 Authors: Georgescu MM, Li Y, Islam MZ, Notarianni C, Sun H, Olar A, Fuller GN Abstract Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as...
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool.
Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool. Oncotarget. 2019 Jun 18;10(40):4026-4037 Authors: Sakhdari A, Moghaddam PA, Ok CY, Walter O, Tomaszewicz K, Caporelli ML, Meng X, LaFemina J, Whalen G, Belkin E, Zivny J, Wassef W, Woda BA, Hutchinson LM, Cosar EF Abstract Objective: Better tools are needed for early diagnosis and classification of pancreatic cystic lesions (PCL) to trigger intervention...
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019 Jun 18;10(40):4018-4025 Authors: Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ Abstract The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive...
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
ETHE1 overexpression promotes SIRT1 and PGC1α mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer.
ETHE1 overexpression promotes SIRT1 and PGC1α mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer. Oncotarget. 2019 Jun 18;10(40):4004-4017 Authors: Witherspoon M, Sandu D, Lu C, Wang K, Edwards R, Yeung A, Gelincik O, Manfredi G, Gross S, Kopelovich L, Lipkin S Abstract Ethylmalonic Encephalopathy Protein 1 (ETHE1) is a sulfur dioxygenase that regulates cellular H2S levels. We previously demonstrated...
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Targeted therapy in CLL: changing the treatment paradigm.
Targeted therapy in CLL: changing the treatment paradigm. Oncotarget. 2019 Jun 18;10(40):4002-4003 Authors: Schneider C, Steinbrecher D, Stilgenbauer S PMID: 31258844 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
An emerging role of CD9 in stemness and chemoresistance.
An emerging role of CD9 in stemness and chemoresistance. Oncotarget. 2019 Jun 18;10(40):4000-4001 Authors: Ullah M, Akbar A, Thakor AS PMID: 31258843 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
From rare to well-done: importance of rare tumors in cancer therapeutic advances.
From rare to well-done: importance of rare tumors in cancer therapeutic advances. Oncotarget. 2019 Jun 18;10(40):3998-3999 Authors: Duffaud F, Piperno-Neumann S, Penel N, Blay JY PMID: 31258842 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Advanced MRI in neuro-oncology: can we proceed without inclusion of energy metabolism?
Advanced MRI in neuro-oncology: can we proceed without inclusion of energy metabolism? Oncotarget. 2019 Jun 18;10(40):3994-3995 Authors: Stadlbauer A, Buchfelder M, Dörfler A, Oberndorfer S PMID: 31258841 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment.
Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment. Oncotarget. 2019 Jun 18;10(40):3991-3993 Authors: Pileri SA, Vegliante MC, Ciavarella S PMID: 31258840 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
VEGF-C as a putative therapeutic target in cancer.
VEGF-C as a putative therapeutic target in cancer. Oncotarget. 2019 Jun 18;10(40):3988-3990 Authors: Michaelsen SR, Poulsen HS, Hamerlik P PMID: 31258839 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Cancer vaccines: what's next?
Cancer vaccines: what's next? Oncotarget. 2019 Jun 18;10(40):3985-3987 Authors: Depil S, Bonaventura P, Alcazer V PMID: 31258838 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
The non-random landscape of somatically-acquired uniparental disomy in cancer.
The non-random landscape of somatically-acquired uniparental disomy in cancer. Oncotarget. 2019 Jun 18;10(40):3982-3984 Authors: Erola P, Torabi K, Miró R, Camps J PMID: 31258837 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h
Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?
Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next? Oncotarget. 2019 Jun 18;10(40):3979-3981 Authors: Msaouel P, Carugo A, Genovese G PMID: 31258836 [PubMed]
Oncotarget,Albany, N.Y. : Impact Journals,http://www.impactjournals.com/oncotarget/
1h

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου

Translate